Protox safely treats first two cohorts in phase 1 trial of PRX302 in prostate cancer

By Lisa Kerner

Charlotte, N.C., Aug. 10 - Protox Therapeutics Inc. said the first two cohorts of patients in its phase 1 clinical trial of PRX302 for prostate cancer have been safely treated. Dose escalation to the third cohort will begin this month.

PRX302's therapeutic activity will be monitored through changes in PSA levels and prostate biopsies after 30 days.

The University of Vermont will join lead center Scott & White Memorial Hospital in the trial.

"We look forward to reporting interim results based on a larger number of patients in the fourth quarter," president and chief executive officer Fahar Merchant said in a company news release.

Preclinical studies have shown that PRX302 can destroy prostate tissue in the presence of prostate-specific antigen, according to the release.

Additionally, Protox said it completed a Preclinical Trial Application meeting with Health Canada about its planned phase 1 clinical trial of PRX302 for the treatment of benign prostatic hyperplasia (enlarged prostate). The company plans to submit a Clinical Trial Application in the third quarter of 2006.

Vancouver, B.C.-based Protox is a development-stage company advancing novel, targeted protein toxin therapeutics for the treatment of cancer and other proliferative diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.